Tranexamic acid

Generic Name
Tranexamic acid
Brand Names
Cyklokapron, Lysteda
Drug Type
Small Molecule
Chemical Formula
C8H15NO2
CAS Number
1197-18-8
Unique Ingredient Identifier
6T84R30KC1
Background

Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.

It was first patented in 1957 and received its initial US approval in 1986.

Indication

Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.

Associated Conditions
Bleeding, Heavy Menstrual Bleeding, Hereditary Angioedema (HAE)
Associated Therapies
-

Intravenous vs. Topical Tranexamic Acid in Revision THA (VITALITY-X)

First Posted Date
2016-10-19
Last Posted Date
2016-10-19
Lead Sponsor
Mount Sinai Hospital, Canada
Target Recruit Count
160
Registration Number
NCT02938962
Locations
🇨🇦

Mount Sinai Hospital, Toronto, Ontario, Canada

Tranexamic Acid for Preventing Postpartum Hemorrhage After Cesarean Section

First Posted Date
2016-10-18
Last Posted Date
2016-10-18
Lead Sponsor
Shanghai First Maternity and Infant Hospital
Target Recruit Count
6700
Registration Number
NCT02936661

Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2016-10-12
Last Posted Date
2021-11-30
Lead Sponsor
University of California, Davis
Target Recruit Count
35
Registration Number
NCT02930941
Locations
🇺🇸

University of California, Davis Medical Center, Sacramento, California, United States

Study of Local Administration of DepoTXA for Reduced Postsurgical Bleeding in Subjects Undergoing TKA

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2016-10-04
Last Posted Date
2020-12-11
Lead Sponsor
Pacira Pharmaceuticals, Inc
Target Recruit Count
16
Registration Number
NCT02922582
Locations
🇺🇸

Ortho Arizona, Gilbert, Arizona, United States

🇺🇸

University of Miami Hospital, Miami, Florida, United States

🇺🇸

Ohio State University/Wexner Medical Center, Columbus, Ohio, United States

and more 2 locations

The Effect of Topical Tranexamic Acid on Postoperative Bleeding From Superficial Wounds

First Posted Date
2016-09-28
Last Posted Date
2023-11-28
Lead Sponsor
St. Olavs Hospital
Target Recruit Count
36
Registration Number
NCT02918201
Locations
🇳🇴

St Olavs Hospital, Kirurgisk klinikk, Trondheim, Norway

🇳🇴

Haukeland University Hospital, Burn Unit & Dept of Plastic Surgery, Bergen, Norway

IV Tranexamic Acid Prior to Hysterectomy

First Posted Date
2016-09-22
Last Posted Date
2022-08-09
Lead Sponsor
Northwestern University
Target Recruit Count
71
Registration Number
NCT02911831
Locations
🇺🇸

Northwestern University - Northwestern Medicine, Lavin Family Pavillion, Chicago, Illinois, United States

Safety and Efficacy of Oral TXA in Reducing Blood Loss and Transfusion in Hip Fractures

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2016-09-21
Last Posted Date
2019-07-29
Lead Sponsor
Yale University
Target Recruit Count
6
Registration Number
NCT02908516
Locations
🇺🇸

Yale New Haven Hospital, New Haven, Connecticut, United States

Treatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist

First Posted Date
2016-08-15
Last Posted Date
2022-04-04
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
64
Registration Number
NCT02866838
Locations
🇨🇭

Stroke Center, University Hospital Basel, Basel, Switzerland

Tranexamic Acid and Blood Clots in Knee Surgery

Completed
Conditions
Interventions
First Posted Date
2016-08-15
Last Posted Date
2019-05-20
Lead Sponsor
University of New Mexico
Target Recruit Count
25
Registration Number
NCT02867163
Locations
🇺🇸

Sandoval Regional Medical Center, Rio Rancho, New Mexico, United States

Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: A Pilot and Feasibility Study

First Posted Date
2016-07-21
Last Posted Date
2021-09-05
Lead Sponsor
Daniel Nishijima, MD, MAS
Target Recruit Count
31
Registration Number
NCT02840097
Locations
🇺🇸

University of California, Davis, Sacramento, California, United States

🇺🇸

Nationwide Children's Hospital, Columbus, Ohio, United States

🇺🇸

Primary Children's Hospital, Salt Lake City, Utah, United States

and more 1 locations
© Copyright 2024. All Rights Reserved by MedPath